Key takeaways
- The difference between hCG and enclomiphene is where each one acts: hCG is an injection that does the job of luteinizing hormone (LH) directly at the testes, while enclomiphene is a pill that prompts the pituitary to release more of its own LH and follicle-stimulating hormone (FSH).
- hCG and enclomiphene work at two different points of the same hormone chain, which runs from the hypothalamus to the pituitary to the testes.
- Neither hCG nor enclomiphene is clearly better for raising testosterone, because both raise it and no published trial has compared enclomiphene with hCG head to head.
- Enclomiphene vs hCG on TRT favors hCG, because testosterone therapy switches off the pituitary signal that enclomiphene depends on, while hCG works without it.
- For fertility, hCG and enclomiphene both support sperm production, but in different men: enclomiphene in men with a working pituitary who are not on testosterone, and hCG in men on TRT, men recovering from it, or men with pituitary failure.
Short Answer
What Is the Difference Between hCG and Enclomiphene?
The difference between hCG and enclomiphene is where each one acts: hCG is an injection that does the job of luteinizing hormone (LH) directly at the testes, while enclomiphene is a pill that prompts the pituitary to release more of its own LH and follicle-stimulating hormone (FSH). Both raise a man's own testosterone instead of replacing it, and both are used when protecting sperm production matters. They are not interchangeable, because one bypasses the brain and the other depends on it.
Their regulatory status differs as much as their mechanism. hCG is an FDA-approved drug, sold as Pregnyl and Novarel, and both labels list selected cases of hypogonadotropic hypogonadism in males among their uses. Prescribing hCG alongside testosterone replacement therapy (TRT), or to raise testosterone in men without a pituitary cause, is off-label. Enclomiphene is unapproved: it is not FDA-approved for any use, and what US physicians prescribe is compounded.
Protocol Health prescribes both enclomiphene and hCG, so we have a commercial interest in this comparison, and this page gives the risks the same space as the benefits. If you want to know which one your labs point to, our short assessment is the first step.
| hCG | Enclomiphene | |
|---|---|---|
| How it is taken | Injection | Oral tablet |
| Where it acts | Testes (acts like LH) | Hypothalamus and pituitary |
| Needs a working pituitary | No | Yes |
| Effect on your own LH and FSH | Does not raise them | Raises both |
| Works alongside full-dose TRT | Yes, small studies | Not tested; unlikely by mechanism |
| Sperm and fertility evidence | Small series, including pregnancies | Sperm counts kept normal in trials |
| FDA status | Approved for specific uses; off-label in TRT | Not FDA-approved for any use |
| Main label or class warnings | Fluid retention, gynecomastia, tumor contraindications | No label; parent drug warns of visual symptoms |
Bottom line: hCG and enclomiphene differ in route, in where they act and in FDA status, and the right one depends on whether your pituitary still works and whether you are on testosterone.
Mechanism
How Do hCG and Enclomiphene Work?
hCG and enclomiphene work at two different points of the same hormone chain, which runs from the hypothalamus to the pituitary to the testes. The pituitary releases LH, which tells the Leydig cells in the testes to make testosterone, and FSH, which supports sperm production. Testosterone and estrogen then signal back to the brain to slow that release.
Enclomiphene works at the top of the chain. It is the trans isomer of clomiphene, and it blocks estrogen's feedback signal at the hypothalamus and pituitary, so the pituitary keeps releasing LH and FSH and the testes respond by making more testosterone. In a randomized phase II trial in men with secondary hypogonadism, enclomiphene raised morning testosterone and LH to levels similar to a 1% testosterone gel, raised FSH, and conserved sperm counts. Our reading of that mechanism is that enclomiphene is unlikely to help a man whose pituitary cannot make LH, because it needs the pituitary to answer.
hCG works at the bottom of the chain. It acts on the same receptor as LH on the Leydig cells, so it switches testosterone production on without any signal from the pituitary. That is why the Pregnyl label lists hypogonadism secondary to a pituitary deficiency among its uses. hCG does not replace FSH, so men with pituitary failure who are trying to conceive sometimes need FSH as well. In a two-clinic case series of men with testosterone-related azoospermia, physicians paired hCG with clomiphene, tamoxifen, anastrozole or recombinant FSH according to their own preference.
In mechanism terms, enclomiphene turns up the brain's own signal and hCG stands in for it, and that single difference drives every other contrast between them.
Testosterone
Is hCG Better Than Enclomiphene for Raising Testosterone?
Neither hCG nor enclomiphene is clearly better for raising testosterone, because both raise it and no published trial has compared enclomiphene with hCG head to head.
The closest randomized comparison used clomiphene, the parent drug, not enclomiphene. In a three-month randomized study of 282 men with hypogonadism who wanted to preserve fertility, clomiphene, twice-weekly hCG injections and the combination all raised testosterone, with no statistically significant difference between the groups. Symptom scores improved most with the combination. Mean testosterone in that study started very low, at 2.31 nmol/L, and finished at 5.17 nmol/L, a 223% rise, so the men were more deficient than most who ask about these drugs. Clomiphene contains both of its isomers, so this result does not transfer directly to enclomiphene.
A 2025 meta-analysis of randomized trials pooled clomiphene and enclomiphene together as selective estrogen receptor modulators (SERMs). It reported higher total testosterone with SERM therapy, and with SERM plus hCG, than with hCG alone, and no significant difference in total testosterone between SERMs and testosterone gel. Pooling two drugs and the small number of hCG trials limit what it says about enclomiphene specifically.
Enclomiphene's own trials compared it with testosterone gel, not hCG. In two phase III trials in overweight men aged 18 to 60 with secondary hypogonadism, enclomiphene and gel both raised total testosterone over 16 weeks, while LH, FSH and sperm concentration were maintained on enclomiphene and fell on gel. In a 12-man phase IIb study, testosterone returned to pretreatment values one month after enclomiphene was stopped, so the effect lasts only while the drug is taken. In that same study, enclomiphene raised sperm counts in seven of seven men at three months and six of six at six months, while gel failed to lift counts above 20 million/mL in any of five men at three months.
For raising testosterone alone, the evidence makes hCG and enclomiphene roughly comparable, and the better choice rests on route, pituitary function and whether TRT is part of the plan.
On TRT
Enclomiphene vs hCG on TRT
Enclomiphene vs hCG on TRT favors hCG, because testosterone therapy switches off the pituitary signal that enclomiphene depends on, while hCG works without it.
In a randomized study of 29 healthy men given weekly testosterone enanthate, LH and FSH fell to 5% and 3% of baseline, and testosterone inside the testes fell 94% in the placebo group. Low-dose hCG given every other day at 125, 250 or 500 IU kept intratesticular testosterone between 25% below and 26% above baseline. The study ran three weeks and did not measure sperm counts. These are the doses the study tested, not a regimen to follow. The same study measured baseline serum testosterone at only 1.2% of the level inside the testes, which is why a normal blood level on TRT says little about what the testes are doing.
A retrospective review of 26 men on TRT with intramuscular hCG 500 IU every other day found no change in semen parameters during follow-up (mean 6.2 months), no man became azoospermic, and 9 of the 26 contributed to a pregnancy with their partner. Serum testosterone rose from a mean of 207 to 1,056 ng/dL during treatment, which reflects the TRT rather than the hCG. It had no comparison group. A 2025 review of fertility-sparing approaches reads the literature the same way: low-dose hCG given with testosterone sustains intratesticular testosterone and sperm production.
No trial has tested enclomiphene added to full-dose TRT. Our inference from the mechanism, which matches our TRT vs enclomiphene guide, is that enclomiphene would be trying to amplify a signal the testosterone has already suppressed. On TRT, hCG is the option with data behind it, and enclomiphene is more often an alternative to TRT than an add-on.
Fertility
hCG and Enclomiphene for Fertility
For fertility, hCG and enclomiphene both support sperm production, but in different men: enclomiphene in men with a working pituitary who are not on testosterone, and hCG in men on TRT, men recovering from it, or men with pituitary failure.
Fertility is the reason either drug comes up, because exogenous testosterone suppresses sperm production. A review of testosterone therapy and male infertility describes that suppression and notes that in hormonal-contraception studies most men regained normal sperm production within a year of stopping. It names hCG and SERMs such as clomiphene as the therapies that protect the testis.
Enclomiphene's fertility data are sperm counts, not pregnancies. In its phase II and phase III trials, sperm concentration stayed in the normal range on enclomiphene while it fell on testosterone gel (Wiehle 2014; Kim 2016). hCG's data include pregnancies, from small uncontrolled series: 9 of 26 men in the TRT plus hCG review, and in that case series of 49 men with testosterone-related azoospermia or severe oligospermia, sperm returned or improved in 47 (95.9%) on hCG-based combination therapy, at an average of 4.6 months. No man in that series stopped hCG or the added drugs because of adverse events, though a retrospective chart review is the weakest kind of evidence for that point.
Neither drug has a randomized trial with live birth as the outcome. The fertility choice between hCG and enclomiphene follows the man's starting point, and a semen analysis before and during treatment is how either one is judged.
Testicular Size
hCG vs Enclomiphene for Testicular Atrophy
For testicular atrophy, hCG vs enclomiphene comes down to the cause: hCG targets shrinkage caused by TRT, while enclomiphene addresses low LH in men who are not taking testosterone.
Most of the testis is sperm-producing tubules, and those depend on high testosterone inside the testes. When TRT suppresses LH, intratesticular testosterone falls, which is the likely mechanism behind shrinkage on testosterone; Coviello 2005 measured the intratesticular drop, not testicular size (Coviello 2005). hCG restores that intratesticular signal directly. Enclomiphene raises LH and FSH from the pituitary, which is the same signal sent from upstream, but only if testosterone therapy is not holding the pituitary down.
Neither drug has a trial that used testicular size as its main outcome, so any claim that either reverses atrophy is inference from hormone and sperm data. That is our reading, not a measured result. For testicular atrophy on TRT, hCG fits the mechanism; for low LH without TRT, enclomiphene fits it.
Combining
Can You Take hCG and Enclomiphene Together?
You can take hCG and enclomiphene together under a physician's care, but the evidence for the combination is thin and comes mostly from clomiphene, not enclomiphene.
In the randomized study of 282 men, clomiphene plus hCG raised testosterone no more than either drug alone over three months, though symptom scores improved more with the combination. The 2025 meta-analysis found total testosterone higher with SERM plus hCG and with a SERM alone than with hCG alone. In that case series, hCG was paired with clomiphene, tamoxifen, anastrozole or FSH, and recovery did not differ by the added drug.
No published trial has tested enclomiphene combined with hCG. A combination also means two sets of risks, possibly including a larger rise in estradiol, and two drugs to monitor. Taking hCG and enclomiphene together is a case-by-case physician decision rather than a default stack, and labs before and during treatment show whether two drugs are doing more than one.
Side Effects
Enclomiphene vs hCG Side Effects
Enclomiphene vs hCG side effects differ in kind: hCG's come from an FDA label and mostly reflect extra androgen and estrogen, while enclomiphene has no FDA label, so its side effects are inferred from small trials and from its parent drug.
The Pregnyl label contraindicates hCG in men with breast or prostate tumors or tumors of the hypothalamus or pituitary, in uncontrolled thyroid, adrenal or pituitary disorders, and after a prior hypersensitivity reaction to gonadotropins. It also warns that anaphylaxis and venous or arterial blood clots have been reported with gonadotropin therapy. It advises caution in heart or kidney disease, hypertension, epilepsy, migraine and asthma, because the androgen production hCG drives may cause fluid retention, and it lists gynecomastia among adverse reactions. Because hCG raises testosterone inside the testes, estradiol can rise too, which is one reason it is checked on labs.
Enclomiphene has no approved label and so no official adverse-reaction list. Its parent drug's clomiphene label warns of blurring and other visual symptoms that increase with total dose and duration and may be irreversible. The clomiphene label also lists pulmonary embolism, thrombophlebitis and retinal thrombosis among postmarketing adverse reactions. Whether that warning applies to enclomiphene alone has not been settled in trials, and we treat any visual change on enclomiphene as a reason to contact the prescriber. In a Baylor chart review of 66 men who moved from clomiphene to enclomiphene, decreased libido, reduced energy and mood changes were less frequent on enclomiphene, and estradiol fell slightly on enclomiphene while it rose on clomiphene; median testosterone rose by 166 ng/dL on enclomiphene against 98 ng/dL on clomiphene, a difference that was not statistically significant. The review was retrospective, not randomized, and every man had taken clomiphene first.
Enclomiphene raised estradiol along with testosterone in its phase II trial, so both drugs can push estrogen up. Neither has long-term safety data in men. The side effects of both hCG and enclomiphene are known only over months, and labs plus symptoms are how they are tracked.
FDA Status
Is hCG or Enclomiphene FDA Approved?
hCG is FDA approved for specific uses, and enclomiphene is not FDA approved for any use.
The Pregnyl and Novarel labels list three indications: prepubertal cryptorchidism not due to anatomical obstruction, selected cases of hypogonadotropic hypogonadism secondary to a pituitary deficiency in males, and induction of ovulation in certain infertile women. Both labels state that hCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. Using hCG to support testosterone alongside TRT, or in men without a pituitary cause, is off-label.
Enclomiphene is unapproved, and US enclomiphene is compounded; the FDA's compounding questions and answers state that compounded drugs are not FDA-approved. In June 2022, the FDA proposed that enclomiphene citrate not be included on the list of bulk substances pharmacies may compound under section 503A, and its Pharmacy Compounding Advisory Committee voted 8 to 4 against placing it on the list, with several members citing a lack of clinical efficacy evidence. No final decision has followed. On the FDA's list of nominated 503A bulk drug substances, updated May 14, 2026, enclomiphene citrate sits in Category 1, under evaluation, which is a holding status and not an approval.
On FDA status, hCG is an approved drug used off-label for most male hormone goals, while enclomiphene is an unapproved compounded drug that the FDA is still evaluating.
Choosing
Is Enclomiphene as Good as hCG?
Enclomiphene is as good as hCG for some men and the wrong choice for others, and the deciding factors are pituitary function, TRT status, fertility timing and comfort with injections.
The decision starts with a diagnosis. The Endocrine Society guideline recommends diagnosing hypogonadism only with consistent symptoms and unequivocally low morning fasting testosterone, confirmed on a repeat test. LH and FSH then show whether the problem sits in the testes or above them. A man whose testosterone is low with low or normal LH has secondary hypogonadism, which is the group enclomiphene was tested in. A man with low testosterone and a pituitary disorder falls under the hCG label's indication.
Our reading of the evidence, for a physician to apply rather than a rule to follow: enclomiphene suits a man not on testosterone, with low or normal LH and a pituitary that responds, who prefers a pill and wants to keep sperm production. hCG suits a man on TRT who wants to protect testicular function or fertility, a man with pituitary failure, or a man recovering sperm production after testosterone. A man with primary testicular failure, where LH is already high, is unlikely to gain from either, because both work by sending a stronger signal to testes that cannot answer it.
Other fertility-sparing options exist beyond these two. A 2025 review describes short-acting intranasal testosterone and oral testosterone undecanoate keeping FSH and LH within reference ranges, though semen data for those remain limited.
Enclomiphene matches hCG only in the man whose pituitary still answers, and labs are what show which man you are.
Our Approach
hCG vs Enclomiphene at Protocol Health
hCG vs enclomiphene at Protocol Health is a physician decision made after a hormone panel, your history and a conversation about fertility. Protocol Health prescribes enclomiphene, hCG and testosterone, so we have a commercial interest in which you choose, and a physician may decide neither fits.
Our guides to hCG for men, enclomiphene for men and Clomid for men cover each drug on its own, including the isomer difference between clomiphene and enclomiphene.
In-person care is at our Scarsdale, NY clinic, and telehealth visits are available in New York, New Jersey, Connecticut, Florida and California. Start with our short assessment to see whether a consultation fits.
hCG vs enclomiphene at Protocol Health means the choice follows your labs and goals, with the risks of each discussed before anything is prescribed.
FAQ
Frequently Asked Questions
Is hCG or enclomiphene better?
Neither is better for every man. hCG acts on the testes and fits men on TRT or with pituitary failure. Enclomiphene acts through the pituitary and fits men not on testosterone whose pituitary responds. No trial has compared the two head to head.
Can hCG be taken with enclomiphene?
Yes, under a physician's care, but no published trial has tested the pair. A randomized study of clomiphene, enclomiphene's parent drug, plus hCG found testosterone rose no more than with either drug alone over three months.
Is enclomiphene hCG?
No. Enclomiphene is an oral selective estrogen receptor modulator that acts on the brain. hCG is an injected hormone that acts like LH on the testes.
Does hCG make men feel better?
It can when low testosterone is causing symptoms, but the evidence is limited. In one randomized study, symptom scores improved on hCG, clomiphene and the combination, most with the combination. The main TRT plus hCG studies measured hormones and sperm, not how men felt.
Is there anything better than enclomiphene?
That depends on the goal. For men on TRT, hCG has more evidence for protecting testicular function. For men not planning children, FDA-approved testosterone may be the simpler option, in our view. Enclomiphene is not FDA-approved for any use.
Which is better for fertility, hCG or enclomiphene?
It depends where you start. On TRT, small hCG studies showed preserved semen and pregnancies. Off TRT, enclomiphene kept sperm counts normal in trials while testosterone gel lowered them. Neither has a trial measuring live births.
Explore
Related at Protocol Health
Talk to a physician about hCG or enclomipheneMedical disclaimer
This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.
Important safety information
References
- Pregnyl. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e94155f-19be-4944-b197-be4edbb4faf9
- Novarel. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac6918ff-9dc3-40d9-8619-54b26e4bdfc8
- randomized phase II trial. PubMed. https://pubmed.ncbi.nlm.nih.gov/25044085/
- a two-clinic case series. PubMed. https://pubmed.ncbi.nlm.nih.gov/25904023/
- three-month randomized study of 282 men with hypogonadism who wanted to preserve fertility. PubMed. https://pubmed.ncbi.nlm.nih.gov/29772111/
- 2025 meta-analysis of randomized trials. PubMed. https://pubmed.ncbi.nlm.nih.gov/41066380/
- two phase III trials. PubMed. https://pubmed.ncbi.nlm.nih.gov/26496621/
- 12-man phase IIb study. PubMed. https://pubmed.ncbi.nlm.nih.gov/23530575/
- randomized study of 29 healthy men. PubMed. https://pubmed.ncbi.nlm.nih.gov/15713727/
- retrospective review of 26 men. PubMed. https://pubmed.ncbi.nlm.nih.gov/23260550/
Show all 18 references
- 2025 review of fertility-sparing approaches. PubMed. https://pubmed.ncbi.nlm.nih.gov/41522318/
- review of testosterone therapy and male infertility. PubMed. https://pubmed.ncbi.nlm.nih.gov/26813847/
- clomiphene label. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b56e04f0-490d-4f10-a0ed-31c288f4f4c5
- Baylor chart review of 66 men. PubMed. https://pubmed.ncbi.nlm.nih.gov/39434750/
- FDA's compounding questions and answers. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- voted 8 to 4. U.S. Food and Drug Administration. https://www.fda.gov/media/161293/download
- list of nominated 503A bulk drug substances. U.S. Food and Drug Administration. https://www.fda.gov/media/94155/download
- Endocrine Society guideline. PubMed. https://pubmed.ncbi.nlm.nih.gov/29562364/
Why trust our physicians
Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.
- Medically reviewed by
- Richard Dentico, MD on
- Written by
- Protocol Health Editorial Team
- First published
- Last updated
See an error? Email care@protocolhealthmd.com and we will review it.
More on Testosterone & TRT
- What Is Free Testosterone? Free vs Total Testosterone, SHBG and Testing
- Does Testosterone Make You Gain Weight? What the Trials Show
- Testosterone Levels by Age Chart: What Is Normal for Men and Women?
- TRT in California: Who Can Prescribe It and What the Law Requires
